Cytokinetics Drug Shows Strong Results in Heart Patients
- Obstructive Hypertrophic Cardiomyopathy (HCM) is a common, inherited heart condition affecting an estimated 1 in 200 people.
- New data presented Saturday from the Phase 3 MAPLE-HCM study demonstrate a notable advantage for Cytokinetics' experimental drug,aficamten,over the commonly prescribed beta-blocker metoprolol in newly diagnosed HCM patients.
- This difference is clinically meaningful, suggesting aficamten can improve a patient's ability to perform physical activity.
“`html
Aficamten Shows Promise in Obstructive Hypertrophic Cardiomyopathy, FDA Review Ongoing
Table of Contents
What is Obstructive Hypertrophic Cardiomyopathy (HCM)?
Obstructive Hypertrophic Cardiomyopathy (HCM) is a common, inherited heart condition affecting an estimated 1 in 200 people. It’s characterized by a thickening of the heart muscle, particularly the left ventricle, which can obstruct blood flow and lead to symptoms like shortness of breath, chest pain, and fatigue. HCM can also increase the risk of sudden cardiac death.
MAPLE-HCM Study Results: Aficamten vs. Metoprolol
New data presented Saturday from the Phase 3 MAPLE-HCM study demonstrate a notable advantage for Cytokinetics’ experimental drug,aficamten,over the commonly prescribed beta-blocker metoprolol in newly diagnosed HCM patients. Aficamten, administered as a daily pill, resulted in a 1.1-point gain in peak oxygen uptake (VO2 peak), a key measure of exercise capacity. Conversely, patients treated with metoprolol experienced a 1.2-point loss in VO2 peak.
This difference is clinically meaningful, suggesting aficamten can improve a patient’s ability to perform physical activity. VO2 peak is a widely accepted metric used to assess cardiovascular fitness and is often used as a prognostic indicator in heart failure.
| Treatment Group | Change in Peak Oxygen Uptake (VO2 peak) |
|---|---|
| Aficamten | +1.1 points |
| metoprolol | -1.2 points |
Aficamten’s FDA Review and Potential Impact
Aficamten is currently under review by the Food and Drug Administration (FDA) as a potential treatment for obstructive HCM. The FDA is expected to make a decision by .These new study results are likely to bolster the drug’s chances of approval and could broaden its potential use beyond the initial target population.
Currently, treatment options for HCM are limited and often focus on managing symptoms. beta-blockers like metoprolol are frequently prescribed, but they can sometimes worsen symptoms in certain patients. Aficamten represents a novel approach,targeting the underlying mechanism of the disease by reducing excessive heart muscle contraction.
How Aficamten Works: A Novel Mechanism
Aficamten is a selective cardiac myosin inhibitor. Unlike beta-blockers which slow the heart rate and reduce contractility generally, aficamten specifically targets the myosin protein responsible for muscle contraction. By modulating this protein, aficamten aims to reduce the obstruction in the left ventricle without significantly impacting overall heart function.